Dermatology Reports
Cure8 research brief
Why This Matters
Patients and clinicians often face trade-offs when managing overlapping immune-mediated diseases. This report shows how past thromboembolic events and disease remission status can steer therapy away from JAK inhibitors toward targeted biologics.
Who Should Pay Attention
Clinicians treating patients with coexisting atopic dermatitis and inflammatory bowel disease, patients with AD and UC considering systemic therapy, and specialists managing biologic and JAK-inhibitor safety.
Study Snapshot
Story typeResearch paper
Evidence typeResearch paper
Source depthJournal abstract
What To Know
This is a single-case report describing treatment decisions for overlapping AD and UC. The authors explain the immunologic overlap (Th2/IL-13) and note prior poor responses to methotrexate, tralokinumab, and dupilumab.
Because of prior thromboembolic events, the team excluded upadacitinib despite its potential to treat both conditions, and they discontinued infliximab after colonoscopy showed remission. Lebrikizumab (anti–IL-13) was chosen for skin disease; the report does not provide outcomes beyond stating the patient is in follow-up.
Keep In Mind
This is an abstract-level case report in a dermatology journal. It describes clinical reasoning and a treatment choice (lebrikizumab) but does not report long-term outcomes or broader evidence of safety in UC patients.
Source Details
Review the original publication for the complete reporting, methods, and context.
Research paper
Evidence type derived from source or registry metadata.
PublicationDermatology Reports
PublisherPAGEPress Publications
AuthorsAssociazione Dermatologi-Venereologi Ospedalieri Italiani e della Sanità Pubblica
Study typeJournal Article
Indexed viaCrossref
Source typeResearch paper
PublishedSep 24, 2026, 12:00 AM
Content availableJournal abstract
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
Sweet’s syndrome during anti-TNF therapy with successful rescue using a JAK inhibitor in refractory ulcerative colitis: a case report and literature review
People with UC can develop severe neutrophilic skin complications like Sweet’s syndrome that may reflect active bowel inflammation even when recent tests suggested remission.
Beyond class switching in multi-refractory inflammatory bowel disease: Nine case reports and review of literature
For people with multi-refractory Crohn’s disease or ulcerative colitis, adding a JAK inhibitor to an existing biologic (advanced combination therapy) may convert partial responses into deeper remission in selected cases,...
Upadacitinib as a rescue therapy for steroid- and infliximab-refractory acute severe ulcerative colitis: short- and long-term effectiveness and safety in a multicenter cohort study
For patients and clinicians facing steroid- and infliximab-refractory acute severe ulcerative colitis, upadacitinib may be a third-line medical option that can produce rapid symptom and CRP improvement and allow some...